{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:21:59Z","timestamp":1790767319610,"version":"4.1.0"},"reference-count":83,"publisher":"European Respiratory Society (ERS)","issue":"162","license":[{"start":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T00:00:00Z","timestamp":1640131200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir Rev"],"accepted":{"date-parts":[[2021,10,20]]},"published-print":{"date-parts":[[2021,12,31]]},"abstract":"<jats:p>Pulmonary arterial hypertension (PAH) is a rare condition that is characterised by a progressive increase of pulmonary vascular resistances that leads to right ventricular failure and death, if untreated. The underlying narrowing of the pulmonary vasculature relies on several independent and interdependent biological pathways, such as genetic predisposition and epigenetic changes, imbalance of vasodilating and vasoconstrictive mediators, as well as dysimmunity and inflammation that will trigger endothelial dysfunction, smooth muscle cell proliferation, fibroblast activation and collagen deposition. Progressive constriction of the pulmonary vasculature, in turn, initiates and sustains hypertrophic and maladaptive myocardial remodelling of the right ventricle. In this review, we focus on the role of inflammation and dysimmunity in PAH which is generally accepted today, although existing PAH-specific medical therapies still lack targeted immune-modulating approaches.<\/jats:p>","DOI":"10.1183\/16000617.0161-2021","type":"journal-article","created":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T14:33:15Z","timestamp":1640183595000},"page":"210161","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["Smouldering fire or conflagration? An illustrated update on the concept of inflammation in pulmonary arterial hypertension"],"prefix":"10.1183","volume":"30","author":[{"given":"Fr\u00e9d\u00e9ric","family":"Perros","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0703-2892","authenticated-orcid":false,"given":"Marc","family":"Humbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2499-6829","authenticated-orcid":false,"given":"Peter","family":"Dorfm\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2021,12,22]]},"reference":[{"key":"2024102403592265000_30.162.210161.1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01913-2018"},{"key":"2024102403592265000_30.162.210161.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2015.03.540"},{"key":"2024102403592265000_30.162.210161.3","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.113.004555"},{"key":"2024102403592265000_30.162.210161.4","doi-asserted-by":"crossref","unstructured":"Perros F , Cohen-Kaminsky S , Dorfm\u00fcller P , et al. Inflammation in pulmonary arterial hypertension. In: Abraham D , Handler C , Dashwood M , Coghlan G , eds. Translational Vascular Medicine. London, Springer, 2012; pp. 213\u2013229. doi:10.1007\/978-0-85729-920-8_14","DOI":"10.1007\/978-0-85729-920-8_14"},{"key":"2024102403592265000_30.162.210161.5","unstructured":"Perros F , Soubrier F , Antigny F , et al. Immunology in pulmonary vascular disorders: focus on pulmonary arterial hypertension. In: Carbone RG , Puppo F , Tapson VF , eds. Pulmonary Vascular Disorders. New York, Nova Science Publishers, 2021."},{"key":"2024102403592265000_30.162.210161.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2014.04.007"},{"key":"2024102403592265000_30.162.210161.7","doi-asserted-by":"publisher","DOI":"10.1007\/s13239-012-0115-5"},{"key":"2024102403592265000_30.162.210161.8","doi-asserted-by":"crossref","first-page":"524","DOI":"10.3389\/fphys.2018.00524","article-title":"Endothelial mechanotransduction, redox signaling and the regulation of vascular inflammatory pathways","volume":"9","author":"Chatterjee","year":"2018","journal-title":"Front Physiol"},{"key":"2024102403592265000_30.162.210161.9","doi-asserted-by":"publisher","DOI":"10.1006\/cyto.1999.0533"},{"key":"2024102403592265000_30.162.210161.10","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/978-3-319-63245-2_20","article-title":"Hypoxia and local inflammation in pulmonary artery structure and function","volume":"967","author":"Thompson","year":"2017","journal-title":"Adv Exp Med Biol"},{"key":"2024102403592265000_30.162.210161.11","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2011-0402OC"},{"key":"2024102403592265000_30.162.210161.12","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1165\/rcmb.2015-0404LE","article-title":"Gut\u2013lung connection in pulmonary arterial hypertension","volume":"56","author":"Ranchoux","year":"2017","journal-title":"Am J Respir Cell Mol Biol"},{"key":"2024102403592265000_30.162.210161.13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02379"},{"key":"2024102403592265000_30.162.210161.14","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1164\/rccm.201903-0656CI","article-title":"Beyond the lungs: systemic manifestations of pulmonary arterial hypertension","volume":"201","author":"Nickel","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102403592265000_30.162.210161.15","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1161\/HYPERTENSIONAHA.119.14294","article-title":"Altered gut microbiome profile in patients with pulmonary arterial hypertension","volume":"75","author":"Kim","year":"2020","journal-title":"Hypertens"},{"key":"2024102403592265000_30.162.210161.16","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1165\/rcmb.2017-0102ED","article-title":"Linking vascular remodeling and inflammation in pulmonary arterial hypertension: is there a common root cause?","volume":"57","author":"Thistlethwaite","year":"2017","journal-title":"Am J Respir Cell Mol Biol"},{"key":"2024102403592265000_30.162.210161.17","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.113.007822"},{"key":"2024102403592265000_30.162.210161.18","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.115.014207"},{"key":"2024102403592265000_30.162.210161.19","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1086\/688908","article-title":"Transcription factors, transcriptional coregulators, and epigenetic modulation in the control of pulmonary vascular cell phenotype: therapeutic implications for pulmonary hypertension (2015 Grover Conference series)","volume":"6","author":"Pullamsetti","year":"2016","journal-title":"Pulm Circ"},{"key":"2024102403592265000_30.162.210161.20","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.21.120601.141122"},{"key":"2024102403592265000_30.162.210161.21","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1818"},{"key":"2024102403592265000_30.162.210161.22","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1159\/000114655","article-title":"Understanding the role of CD4+CD25(high) (so-called regulatory) T cells in idiopathic pulmonary arterial hypertension","volume":"75","author":"Perros","year":"2008","journal-title":"Respiration"},{"key":"2024102403592265000_30.162.210161.23","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.110.236927"},{"key":"2024102403592265000_30.162.210161.24","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.117.312058"},{"key":"2024102403592265000_30.162.210161.25","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00159911"},{"key":"2024102403592265000_30.162.210161.26","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61226-3"},{"key":"2024102403592265000_30.162.210161.27","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00094706"},{"key":"2024102403592265000_30.162.210161.28","doi-asserted-by":"publisher","DOI":"10.1186\/1465-9921-12-119"},{"key":"2024102403592265000_30.162.210161.29","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.3390\/ijms22041756","article-title":"Central role of dendritic cells in pulmonary arterial hypertension in human and mice","volume":"22","author":"van Uden","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2024102403592265000_30.162.210161.30","doi-asserted-by":"publisher","DOI":"10.1378\/chest.14-1678"},{"key":"2024102403592265000_30.162.210161.31","doi-asserted-by":"publisher","DOI":"10.1007\/s11684-015-0388-9"},{"key":"2024102403592265000_30.162.210161.32","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201105-0927OC"},{"key":"2024102403592265000_30.162.210161.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2012.04.006"},{"key":"2024102403592265000_30.162.210161.34","first-page":"123","article-title":"Pathology of idiopathic interstitial pneumonias","volume":"9","author":"Hashisako","year":"2016","journal-title":"Clin Med Insights Circ Respir Pulm Med"},{"key":"2024102403592265000_30.162.210161.35","doi-asserted-by":"publisher","DOI":"10.4103\/2045-8932.94842"},{"key":"2024102403592265000_30.162.210161.36","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2053"},{"key":"2024102403592265000_30.162.210161.37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/imm.13029","article-title":"T-cell immunology of the lung: maintaining the balance between host defence and immune pathology","volume":"156","author":"Altmann","year":"2019","journal-title":"Immunology"},{"key":"2024102403592265000_30.162.210161.38","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201208-1364OC"},{"key":"2024102403592265000_30.162.210161.39","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.112.110619"},{"key":"2024102403592265000_30.162.210161.40","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201302-0403OC"},{"key":"2024102403592265000_30.162.210161.41","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.05.00112105"},{"key":"2024102403592265000_30.162.210161.42","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.108.182014"},{"key":"2024102403592265000_30.162.210161.43","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1424774112"},{"key":"2024102403592265000_30.162.210161.44","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1161\/CIRCULATIONAHA.118.033744","article-title":"Bmpr2 mutant rats develop pulmonary and cardiac characteristics of pulmonary arterial hypertension","volume":"139","author":"Hautefort","year":"2019","journal-title":"Circulation"},{"key":"2024102403592265000_30.162.210161.45","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00164713"},{"key":"2024102403592265000_30.162.210161.46","doi-asserted-by":"publisher","DOI":"10.1172\/JCI96462"},{"key":"2024102403592265000_30.162.210161.47","doi-asserted-by":"crossref","unstructured":"Toshner M , Church C , Harbaum L , et al. Mendelian randomisation and experimental medicine approaches to IL-6 as a drug target in PAH. Eur Respir J 2021; in press [https:\/\/doi.org\/10.1183\/13993003.02463-2020].","DOI":"10.1183\/13993003.02463-2020"},{"key":"2024102403592265000_30.162.210161.48","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1002\/art.41309","article-title":"Tumor necrosis factor induces obliterative pulmonary vascular disease in a novel model of connective tissue disease-associated pulmonary arterial hypertension","volume":"72","author":"Bell","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"2024102403592265000_30.162.210161.49","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/1756-185X.12304","article-title":"Preventive and remedial application of etanercept attenuate monocrotaline-induced pulmonary arterial hypertension","volume":"19","author":"Zhang","year":"2016","journal-title":"Int J Rheum Dis"},{"key":"2024102403592265000_30.162.210161.50","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.013111"},{"key":"2024102403592265000_30.162.210161.51","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1164\/rccm.202009-3481OC","article-title":"Safety and efficacy of B-cell depletion with rituximab for the treatment of systemic sclerosis-associated pulmonary arterial hypertension: a multicenter, double-blind, randomised, placebo-controlled trial","volume":"204","author":"Zamanian","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102403592265000_30.162.210161.52","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01899-2018"},{"key":"2024102403592265000_30.162.210161.53","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.drudis.2018.12.001","article-title":"TGF\u03b2 and BMPRII signalling pathways in the pathogenesis of pulmonary arterial hypertension","volume":"24","author":"Tielemans","year":"2019","journal-title":"Drug Discov Today"},{"key":"2024102403592265000_30.162.210161.54","doi-asserted-by":"crossref","first-page":"2045894019883607","DOI":"10.1177\/2045894019883607","article-title":"Cytokines trigger disruption of endothelium barrier function and p38 MAP kinase activation in BMPR2-silenced human lung microvascular endothelial cells","volume":"9","author":"Tielemans","year":"2019","journal-title":"Pulm Circ"},{"key":"2024102403592265000_30.162.210161.55","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1211097"},{"key":"2024102403592265000_30.162.210161.56","doi-asserted-by":"crossref","first-page":"e002087","DOI":"10.1161\/CIRCGEN.118.002087","article-title":"Loss-of-function ABCC8 mutations in pulmonary arterial hypertension","volume":"11","author":"Bohnen","year":"2018","journal-title":"Circ Genom Precis Med"},{"key":"2024102403592265000_30.162.210161.57","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.61200"},{"key":"2024102403592265000_30.162.210161.58","doi-asserted-by":"publisher","DOI":"10.1002\/art.27607"},{"key":"2024102403592265000_30.162.210161.59","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.3390\/biom10091261","article-title":"Implication of potassium channels in the pathophysiology of pulmonary arterial hypertension","volume":"10","author":"Le Ribeuz","year":"2020","journal-title":"Biomolecules"},{"key":"2024102403592265000_30.162.210161.60","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00754-2017"},{"key":"2024102403592265000_30.162.210161.61","doi-asserted-by":"publisher","DOI":"10.1016\/S0958-1669(97)80130-9"},{"key":"2024102403592265000_30.162.210161.62","doi-asserted-by":"publisher","DOI":"10.1016\/j.imlet.2003.11.020"},{"key":"2024102403592265000_30.162.210161.63","doi-asserted-by":"publisher","DOI":"10.1016\/S0143-4160(03)00045-9"},{"key":"2024102403592265000_30.162.210161.64","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.115.020951"},{"key":"2024102403592265000_30.162.210161.65","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2014.10.021"},{"key":"2024102403592265000_30.162.210161.66","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1165\/rcmb.2019-0015OC","article-title":"Comparison of human and experimental pulmonary veno-occlusive disease","volume":"63","author":"Manaud","year":"2020","journal-title":"Am J Respir Cell Mol Biol"},{"key":"2024102403592265000_30.162.210161.67","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1161\/CIRCRESAHA.119.314793","article-title":"Characterisation of Kcnk3-mutated rat, a novel model of pulmonary hypertension","volume":"125","author":"Lambert","year":"2019","journal-title":"Circ Res"},{"key":"2024102403592265000_30.162.210161.68","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awp163"},{"key":"2024102403592265000_30.162.210161.69","doi-asserted-by":"crossref","first-page":"5014","DOI":"10.3390\/ijms22095014","article-title":"KCNK3 mutation causes altered immune function in pulmonary arterial hypertension patients and mouse models","volume":"22","author":"West","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2024102403592265000_30.162.210161.70","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1016\/j.jmb.2019.08.014","article-title":"Ion channels of the islets in type 2 diabetes","volume":"432","author":"Jacobson","year":"2020","journal-title":"J Mol Biol"},{"key":"2024102403592265000_30.162.210161.71","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.drudis.2018.02.008","article-title":"The integrated stress response system in cardiovascular disease","volume":"23","author":"Santos-Ribeiro","year":"2018","journal-title":"Drug Discov Today"},{"key":"2024102403592265000_30.162.210161.72","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2005.03.013"},{"key":"2024102403592265000_30.162.210161.73","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1014465107"},{"key":"2024102403592265000_30.162.210161.74","doi-asserted-by":"publisher","DOI":"10.1126\/science.1246829"},{"key":"2024102403592265000_30.162.210161.75","doi-asserted-by":"publisher","DOI":"10.1038\/nature17186"},{"key":"2024102403592265000_30.162.210161.76","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1016\/j.celrep.2016.10.079","article-title":"Stress kinase GCN2 controls the proliferative fitness and trafficking of cytotoxic T cells independent of environmental amino acid sensing","volume":"17","author":"Van de Velde","year":"2016","journal-title":"Cell Rep"},{"key":"2024102403592265000_30.162.210161.77","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201201-0164OC"},{"key":"2024102403592265000_30.162.210161.78","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00151313"},{"issue":"Suppl. 1","key":"2024102403592265000_30.162.210161.79","first-page":"3","article-title":"Cytokine pleiotropy and redundancy: a view from the receptor","volume":"12","author":"Nicola","year":"1994","journal-title":"Stem Cells"},{"key":"2024102403592265000_30.162.210161.80","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2014.01.008"},{"key":"2024102403592265000_30.162.210161.81","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2012-0532OC"},{"key":"2024102403592265000_30.162.210161.82","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1056\/NEJMoa2024277","article-title":"Sotatercept for the treatment of pulmonary arterial hypertension","volume":"384","author":"Humbert","year":"2021","journal-title":"N Engl J Med"},{"key":"2024102403592265000_30.162.210161.83","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1161\/CIRCULATIONAHA.119.040629","article-title":"Phenotypically silent bone morphogenetic protein receptor 2 mutations predispose rats to inflammation-induced pulmonary arterial hypertension by enhancing the risk for neointimal transformation","volume":"140","author":"Tian","year":"2019","journal-title":"Circulation"}],"container-title":["European Respiratory Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/16000617.0161-2021","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T05:04:16Z","timestamp":1740373456000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/16000617.0161-2021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,22]]},"references-count":83,"journal-issue":{"issue":"162","published-online":{"date-parts":[[2021,12,22]]},"published-print":{"date-parts":[[2021,12,31]]}},"alternative-id":["10.1183\/16000617.0161-2021"],"URL":"https:\/\/doi.org\/10.1183\/16000617.0161-2021","relation":{},"ISSN":["0905-9180","1600-0617"],"issn-type":[{"value":"0905-9180","type":"print"},{"value":"1600-0617","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,22]]}}}